| Literature DB >> 32494851 |
Julia Dlugaiczyk1,2, Maximilian Habs3, Marianne Dieterich4,3,5.
Abstract
OBJECTIVE: Vestibular evoked myogenic potentials (VEMPs) have been suggested as biomarkers in the differential diagnosis of Menière's disease (MD) and vestibular migraine (VM). The aim of this study was to compare the degree of asymmetry for ocular (o) and cervical (c) VEMPs in large cohorts of patients with MD and VM and to follow up the responses. STUDYEntities:
Keywords: Menière’s disease; Saccule; Utricle; Vestibular evoked myogenic potentials; Vestibular migraine
Mesh:
Year: 2020 PMID: 32494851 PMCID: PMC7718204 DOI: 10.1007/s00415-020-09902-4
Source DB: PubMed Journal: J Neurol ISSN: 0340-5354 Impact factor: 4.849
Subjects’ demographic information
| MD ( | VM ( | ||
|---|---|---|---|
| Age (years; mean ± SD) | 58.85 ± 13.85 | 36.03 ± 19.49 | |
| Female: male ratio | 38: 62 (0.6: 1) | 70: 30 (2.3: 1) |
MD Menière’s disease, VM vestibular migraine
Fig. 1Asymmetry ratio (AR) for ocular and cervical vestibular evoked myogenic potentials (o- and cVEMPs) in Menière’s disease (MD) and vestibular migraine (VM) (mean + standard deviation (SD), ns not significant, ***adjusted p value < 0.001). a Comparison of oVEMP ARs between MD and VM, probable versus definite MD (pMD/dMD) and probable versus definite VM (pVM/dVM). No difference was observed between the groups. b Comparison of cVEMP ARs between MD and VM, probable versus definite MD (pMD/dMD) and probable versus definite VM (pVM/dVM). cVEMP amplitude AR was significantly higher in MD than in VM (adjusted p value = 0.0002). c Comparison of o- versus cVEMP amplitude ARs in MD and VM. cVEMP amplitude AR was higher than oVEMP amplitude AR for MD (adjusted p value < 0.0001), but not for VM patients
Asymmetry ratios (ARs) of peak and inter-peak latencies for ocular and cervical vestibular evoked myogenic potentials in subjects with Menière’s disease (MD) and vestibular migraine (VM), mean ± SD
| MD ( | VM ( | Adjusted | |
|---|---|---|---|
| AR n10 peak latency | 0.03 ± 0.03 | 0.03 ± 0.04 | > 0.99 |
| AR p15 peak latency | 0.03 ± 0.02 | 0.03 ± 0.02 | > 0.99 |
| AR n10p15 interval | 0.09 ± 0.08 | 0.08 ± 0.07 | 0.72 |
| AR p13 latency | 0.05 ± 0.05 | 0.04 ± 0.04 | 0.47 |
| AR n23 latency | 0.04 ± 0.04 | 0.03 ± 0.03 | 0.25 |
| AR p13n23 interval | 0.11 ± 0.14 | 0.09 ± 0.07 | 0.60 |
An adjusted p value < 0.05 in the two-sided unpaired t test corrected for multiple comparisons was considered to indicate a significant difference between groups
Fig. 2Serial measurements of the asymmetry ratio for ocular vestibular evoked myogenic potentials (AR oVEMPs, grey squares) and cervical vestibular evoked myogenic potentials (AR cVEMPs, black circles) in two patients with vestibular migraine (VM 1 and VM 2) showing either fluctuating or stable degrees of asymmetry. See Table 3 for a summary of the patients’ clinical data
Fig. 3Serial measurements of the asymmetry ratio for ocular vestibular evoked myogenic potentials (AR oVEMPs, grey squares) and cervical vestibular evoked myogenic potentials (AR cVEMPs, black circles) in two patients with Menière’s disease (MD 1 and MD 2) showing either increasing or stable ARs. See Table 3 for a summary of the patients’ clinical data
Clinical data in patients with follow-up recordings of vestibular evoked myogenic potentials (VEMPs) from Figs. 2 and 3
| Diagnosis and gender | Disease duration (years) | Symptoms | Audio-vestibular test results | |||
|---|---|---|---|---|---|---|
| Baseline | Baseline | Follow-up | Baseline | Follow-up | ||
| VM 1 | pVM f | 7 | Spontaneous and positional vertigo attacks for minutes, clustering over several days; 1x/month; accompanying symptoms: nausea, vomiting, photo-/phonophobia, visual aura, sometimes frontal headache; no history of migraine | Treatment with propranolol (5 mg TID); same frequency of attacks, but reduced severity | SVV tilt to the left (5°), normal PTA, normal calorics, normal vHIT | Recovery of SVV tilt, slightly saccadic smooth pursuit |
| VM 2 | dVM m | 1 | Spontaneous vertigo attacks (ca. 15 min), 2-3x/month; accompanying symptoms: nausea, frontal headache, photophobia; positive migraine history | Moderate daily physical activity (30 min); 0–1 attacks/month from Aug to Oct 2016; 2 attacks/month from Nov 2016 to Jan 2017 | Normal PTA, normal vHIT, right HSN, no hydrops in inner ear MRI | Variable caloric asymmetry (first right, then left hypo-excitability), no HSN |
| MD 1 | dMD left m | 1 | Spontaneous vertigo attacks (up to 12 h), 2x/week; accompanying symptoms: nausea, ear fullness, tinnitus, hearing loss on the left | Apr 2016: patient treated with betahistine dihydrochloride 144 mg TID since Dec 2015, no attacks. Temporary increase in attack frequency in May 2016 (2x/week) and Jan 2017 (1–2×/month), progressive hearing loss and chronic tinnitus on the left. ⇒ Symptom-based adjustment of medication (up to 288 mg betahistine TID) Aug 2017–May 2019: no vertigo attacks, sometimes imbalance. ⇒ Betahistine 96 mg TID | PTA: low-frequency hearing loss on the left, calorics: hypo-excitability on the left (42%), normal vHIT | PTA: progressive low-frequency hearing loss on the left, calorics: progressive hypoexcitability on the left (60%) |
| MD 2 | dMD left m | 8 | Spontaneous vertigo attacks (hours) with ear fullness, tinnitus and hearing loss on the left; Tumarkin drop attacks (seconds) without accompanying ear symptoms | Oct 2015–Dec 2017: patient treated with betahistine dihydrochloride 24 mg TID, no vertigo attacks, no Tumarkin attacks, occasional imbalance. ⇒ Betahistine 24 mg BID Dec 2017–Oct 2019: 3 short attacks with vertigo or leftward sway (sec–min), no falls, progressive hearing loss and tinnitus on the left. ⇒ Betahistine 96 mg TID | PTA: low-frequency hearing loss on the left, normal calorics, normal vHIT | PTA: pantonal hearing loss on the left, normal calorics, normal vHIT |
BID two times a day, dMD definite Menière’s disease, dVM definite vestibular migraine, f female, HSN head-shake nystagmus, m male, MRI magnetic resonance imaging, pVM probable vestibular migraine, PTA pure tone audiogram, SVV subjective visual vertical, TID three times a day, vHIT video head impulse test